Janux Therapeutics (JANX) Interest Expenses (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Interest Expenses data on file, last reported at $28.5 million in Q1 2026.

• On a quarterly basis, Interest Expenses fell 78.27% year-over-year to $28.5 million in Q1 2026; TTM through Mar 2026 was $28.5 million, a 78.27% decrease from a year earlier, with the FY2025 full-year figure at $29.6 million, down 91.82% from the prior year.
• Interest Expenses for Q1 2026 stood at $28.5 million, down from $106.8 million in the prior quarter.
• Over the last five years, Interest Expenses for JANX reached as high as $313.5 million in Q3 2024 and fell as low as $344000.0 in Q4 2022.
• Historically, Interest Expenses has averaged $101.4 million across 5 years, with a median of $37.8 million in 2022.
• Across the five-year window, Interest Expenses soared 1979.37% in 2024 and sank 78.27% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $344000.0 in 2022, then surged by 4282.56% to $15.1 million in 2023, then surged by 1979.37% to $313.5 million in 2024, then slumped by 65.92% to $106.8 million in 2025, then slumped by 73.33% to $28.5 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $28.5 million in Q1 2026, $106.8 million in Q3 2025, and $98.7 million in Q2 2025.